BLRX - CIK 0001498403
The table below shows BioLineRx Ltd.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | $232.00K | $4.50M | $0.00 | - | - | - |
| R&D | $2.33M | $2.23M | $3.01M | $5.39M | $5.14M | $4.64M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $209.00K |
| $1.63M |
| $1.30M |
| $1.05M |
| $1.04M |
| $744.00K |
| Operating income | - | - | - | - | - | - |
| Income tax | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - |
| EPS (diluted) | - | - | - | - | - | - |